Diabetic Nephropathy Market Size, Share, Global Trends, Major Key Players and Geographical Forecast Till 2028

Posted on Aug 4 2022 5:58 AM

"Diabetic Nephropathy Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers, Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors, Mineralocorticoid Receptor Antagonists, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2021-2028"

The increasing prevalence of diabetes around the world is expected to spur opportunities for the market during the forecast period, states Fortune Business Insights in a report, titled “Diabetic Nephropathy Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers, Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors, Mineralocorticoid Receptor Antagonists, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2021-2028” the surge in cardiovascular patients is predicted to contribute positively to the growth of the market in the forthcoming years. The market is anticipated to increase from USD 2.49 billion in 2021 to USD 3.34 billion by 2028 at a CAGR of 4.3% during the 2021 to 2028 period.

Request a Sample PDF Brochure:https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/diabetic-nephropathy-market-102012

Rising Cases of Chronic Diseases to Aid Market Expansion

The increasing prevalence of chronic diseases such as arthritis, asthma, cancer, chronic obstructive pulmonary disease, diabetes, and others is expected to enable speedy growth of the market in the forthcoming years. The increasing cases of obesity and cardiovascular diseases in patients are predicted to foster the healthy growth of the market. Furthermore, the increasing prevalence of diabetes in geriatric patients is likely to create lucrative opportunities for the market in the forthcoming years. As per the World Health Organization, in 2016, an estimated 1.6 million deaths were directly caused by diabetes. Another 2.2 million deaths were attributable to high blood glucose in 2012. Almost half of all deaths attributable to high blood glucose occur before the age of 70 years. WHO also estimates that diabetes was the seventh leading cause of death in 2016.

Developing Healthcare Infrastructure to Stimulate Growth in Asia Pacific

 Geographically, the diabetic nephropathy market size is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the market owing to the prevalence of diabetes. The rising technological advancement in diagnostic imaging and increasing healthcare awareness and monitoring is along with early diagnosis are factors expected to aid expansion in the region. For instance, the National Kidney Disease Education Program (NKDEP) is organized by the US government for creating awareness regarding kidney diseases. Asia Pacific is expected to hold the largest share in the global market during the forecast period owing to the rising geriatric population and developing healthcare infrastructure. The rising government support and healthcare expenditure is expected to stimulate healthy growth of the market.

Available Customizations

With the given market data, Fortune Business Insights offers customizations as per the company’s specific requirements. The following customization options are available for the report:

Product Analysis

  • Product matrix provides detailed product information and comparison

Geographic Analysis

  • Further breakdown of the North American diabetic nephropathy market
  • Further breakdown of the European market
  • Further breakdown of the APAC market
  • Further breakdown of the MEA market
  • Further breakdown of the Latin American market

Company Information

  • Detailed analysis and profiling of additional market players

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/queries/diabetic-nephropathy-market-102012

Primary Research:

Various sources from both the supply and demand sides were interviewed during the primary research process to obtain qualitative and quantitative information for this report. Primary sources included industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations from all segments of the value chain of this industry. To obtain and verify critical qualitative and quantitative information, in-depth interviews were conducted with a variety of primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants.

The Report Lists the Main Companies in the Diabetic Nephropathy Market:

  • Merck & Co., Inc.
  • Abbott
  • Pfizer Inc.
  • Siemens
  • Novartis AG
  • GENERAL ELECTRIC COMPANY
  • Bayer AG
  • Mitsubishi Tanabe Pharma Corporation
  • Renata Limited, and others.

 

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights Pvt. Ltd.

411045, Maharashtra, India.

US: +1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245